Anthem Biosciences Q2 FY26 earnings call

Mon 10 Nov 2025ANTHEM

In brief

Anthem H1 FY26: revenue Rs 1,090 cr, EBITDA margin 41.4%, PAT Rs 309 cr; net cash at Rs 993 cr; 14 commercial molecules.

Management's tone
Confident
What was said
Leaned positive
Guidance
Guidance held
Analyst pushback
Low
Stock, next session
+1.21% (Nifty 50 +0.32%)
  • H1 FY26 consolidated revenue Rs 1,090 cr (CRDMO Rs 926 cr, Specialty Rs 163 cr), with EBITDA Rs 480 cr at 41.4% margin.
  • H1 PAT Rs 309 cr at 26.6% margin; net cash position improved to Rs 993 cr (from Rs 784.8 cr at Q1).
  • Commercial molecules expanded from 10 (at IPO) to 14 in Q2; 4 late-phase assets moved to commercial; late-phase now 6.
  • Unit-II 130 KL expansion complete (CP 6 & CP 7, ~Rs 182 cr capex); Unit-IV greenfield Rs 1,000 cr over 2 years to double capacity.
  • EBITDA margin guidance: upper end of 36-37% normalized (excl ~2-3% FX); H1 reported 41.4% boosted by ~Rs 34 cr FX gain.

An AI read of the company's transcript · the filing

The numbers

The quarter, Q2 FY26

This quarterA year agoLast quarterMargin
Revenue₹550 cr—+1.8%
EBITDA (excl. other income)₹218 cr—+13.8%39.6%
Net profit₹0 cr——0%
EPS (₹)₹3.09—+27.2%

From the company's filed results for the quarter ended 30 Sept 2025 (consolidated), not from the call. EBITDA here excludes other income, so it can differ from the figure management quotes.

Where management's figures differ from the filing

  • H1 EBITDA margin: said 41.4% on Rs 1,090 cr revenue / Rs 480 cr EBITDA; filed Q2 FY26 EBITDA margin 39.6% (excl other income); Q1 was ~38%. Stated 41.4% does not reconcile with 480/1090 = 44.0%; implied H1 average from Q1+Q2 filed would be ~38.8%, not 41.4%.

What moved the numbers, as management explained it

  • ESOP cost dropped from Rs 36 cr in H1 FY25 to Rs 8 cr in H1 FY26 (~Rs 28 cr benefit) on sliding-scale vesting, supporting margin expansion.
  • ~Rs 34 cr FX gain contributed ~2-3% to the 41.4% H1 EBITDA margin; normalized margin is in upper end of 36-37% range. (one-off)
  • Specialty ingredients revenue declined YoY as fungible capacity reallocated to busier CRDMO; CRDMO delivered Rs 926 cr in H1.
  • Other expenses broadly stable YoY in same zip code; combined with revenue scale-up, drove operating leverage and margin expansion.
  • Four new commercial molecule approvals (10 → 14) and 70% utilization on custom synthesis supported the ~26% H1 revenue growth.

The numbers management led with

  • Unit-IV capex commitment: Rs 1,000 Cr for Phase 1 expansion (400 KL custom synthesis + 100 KL fermentation)
  • Commercial molecule count progression: 10 at IPO (Jul 2025) -> 12 in Q1 -> 14 in Q2 (40% growth)
  • CP 6 + CP 7 capacity commissioning: 130 KL commissioned; Rs 182 Cr capex; ~Rs 300 Cr+ revenue potential at 1.6-1.7x asset turnover

Guidance

Guidance on this call

WhatForWhat management saidFiled
EBITDA margin (normalized, excl FX)FY26we will be on the upper end of the 36%-37% that we have always guided towards on the EBITDA margins level38.1%, above the range
Revenue CAGRFY26our CAGR is 20% odd there for the last 10-15 years. We hope to be able to maintain that—
Unit-IV capex (Phase 1)—significant investment we are making there to the tune of Rs. 1,000 Cr—
Unit-IV capacity (custom synthesis + fermentation)—close to about 400 kiloliters on custom synthesis and fermentation about 100 odd kiloliters, give or take—
CP 6 & CP 7 revenue potential (long-term) (CRDMO (Unit-II CP 6 & CP 7))—close to about Rs. 300 plus Cr is what we can look at generating from CP 6, CP 7—
NeoAnthem long-term revenue target (Unit-III (NeoAnthem))—on Rs. 450 Cr capital base, we can generate close to about Rs. 650 Cr of revenues on a long-term basis—
Unit-III revenue target (year-end) (Unit-III (NeoAnthem))FY26Our idea would be to push this number to say Rs. 100 Cr - Rs. 150 Cr, by which time we would be supplying—
Fermentation capacity (NeoAnthem) completion (Unit-III (NeoAnthem))FY26Unit-III fermentation is something what we have to complete, which will happen by the end of this year—

Filed figures are summed from the company's own quarterly results for the whole period (EBITDA excludes other income); where one sits against what was guided is arithmetic, not a judgement.

What changed since the Thu 14 Aug 2025 call

WhatOn the Thu 14 Aug 2025 callOn this call
Commercial molecules count (raised)10 at IPO, expanded to 12 in Q1 FY26; Phase 3 reduced 10 to 814 commercial molecules in Q2 FY26; 4 moved from late phase to commercial
Late phase molecules count (cut)10 at IPO, reduced to 8 in Q1 FY266 in Q2 FY26 as 4 transitioned to commercial
EBITDA margin guidance (restated)~38% zip code for FY26; gross and PAT margins also steadyUpper end of 36-37% on a normalized basis (excluding ~2-3% FX benefit); H1 reported 41.4%
Net cash position (raised)Rs 784.8 cr at end of Q1 FY26Rs 993 cr at end of Q2 FY26
Unit-II custom synthesis capacity (achieved)54 KL commissioned in Q1; balance 134 KL (Unit 2 + NeoAnthem) targeted this calendar year130 KL (CP 6 & CP 7) complete; Unit-II expansion done; ~Rs 182 cr capex
Unit-IV capex and capacity (new)Unit 4 capex to be firmed and shared in coming months (FY26)Rs 1,000 cr capex for phase 1; ~400 KL custom synthesis + 100-200 KL fermentation; 2-year timeline

Guided on earlier calls, and what was filed

WhatForGuidedFiled
EBITDA marginFY26at least 38% (on the Q1 FY26 call)38.1%, within the range

Filed figures are summed from the company's own quarterly results for the whole period (EBITDA excludes other income); where one sits against what was guided is arithmetic, not a judgement.

The business

By business

CRDMO

Custom synthesis and fermentation CDMO; H1 revenue Rs 926 cr; commercial molecules rose from 10 to 14 as 4 moved from late phase; CP 6 & CP 7 (130 KL) commissioned; 70% and 55% utilization.

H1 revenue Rs 926 cr · 70% utilization (custom synthesis) · 55% utilization (fermentation) · CP 6 & CP 7 capex ~Rs 182 cr · 130 KL capacity added

Outlook: Long-term CP 6/CP 7 potential ~Rs 300+ cr at 1.6-1.7x asset turnover; NeoAnthem target Rs 650 cr at 1.4-1.5x on Rs 450 cr asset base; Unit-IV (Rs 1,000 cr capex) to double capacity in 2 years.

Specialty Ingredients

Specialty ingredients; H1 revenue Rs 163 cr; declined YoY as fungible capacity reallocated to busier CRDMO; new CP 6/CP 7 blocks give adequate capacity for both segments going forward.

H1 revenue Rs 163 cr

Outlook: Expected to recover in H2 FY26; H1 decline attributed to capacity reallocation to CRDMO; will continue to fill capacity when CRDMO demand fluctuates.

Balance sheet, capex and funding

  • Net cash position: Rs 993 cr at 30 Sept 2025 (up from Rs 784.8 cr at Q1 FY26), reflecting operating cash generation.
  • Capex spent: ~Rs 182 cr on CP 6 & CP 7 (130 KL) custom synthesis, now commissioned; Unit-II/III major capex complete.
  • Capex plan: Unit-IV greenfield Rs 1,000 cr over next 2 years; will double capacity (400 KL custom synthesis + 100-200 KL fermentation).
  • Unit-III (NeoAnthem) gross block: Rs 350+ cr; will be ~Rs 450+ cr after fermentation block completes by end of calendar 2025.
  • Inventory days reduced to ~105 days as outsourced intermediates replaced by in-house manufacturing; customers also asked for inventory trim.
  • Funding: net cash positive; no major debt raise disclosed; will borrow only if attractively priced (carried from prior call).

The industry, as management sees it

Management sees CRDMO RFP inflows to Indian companies accelerating, with new funding windows opening up for biotech customers. However, investor selectivity has risen — only well-validated projects get funded. Peptides seen as a major long-term runway beyond GLP-1 (oncology, metabolism, obesity). US biotech funding drought has not impacted Anthem yet but is a watch-item.

Risks management named

  • US biotech funding environment more selective; investors funding fewer, higher-quality projects though Anthem not yet impacted
  • Quarterly lumpiness in revenue as biotech customers bunch orders; can mask underlying trend
  • Customer acquisition risk: biotech customers often get acquired after product approval, beyond Anthem's control
  • Specialty ingredients revenue can dip when CRDMO demand pulls fungible capacity away from it

Q&A

Q&A was dominated by capacity build-out discussion (CP6/CP7, Unit-III NeoAnthem, Unit-IV Rs 1,000 Cr greenfield) and pipeline evolution (10→14 commercial, 10→6 late-phase). Pushback was light; analysts sought clarifications on margin guidance (reaffirmed upper end of 36-37%), specialty ingredients volatility (deflected to fungible capacity narrative), and US biotech funding (management played down impact on Anthem). The most material new disclosures were Unit-IV capacity (400 KL custom synthesis + 100 KL fermentation), NeoAnthem long-term Rs 650 Cr revenue on Rs 450 Cr base, peptide capacity scaling potential (16 KL → 32-40 KL), and vertical integration on P29 fermentation for GLP-1.

Not answered directly

  • Customer names for large pharma engagements (declined to name despite repeated probing)
  • Exact approval timing for remaining 6 late-stage molecules (said not in Anthem's hands)
  • Quarterly growth run-rate beyond directional 20% CAGR (asked to bear in mind QoQ lumpiness)

Asked for a number, answered without one

  • Unit-III full revenue timing: Said WIP is Rs 55 cr already; targets Rs 100-150 cr by year-end; commercial revenue kick-up later after FDA inspection.
  • Unit-IV first revenue date: Said Unit-IV will be commissioned in two years; no specific first revenue date provided.
  • Late phase to commercial transition: Said depends on FDA and customer; no specific timeline given; expects some to be second-source additions.
  • Employee headcount for Unit-IV: Said they will need to add people but no specific number; will transfer trained people from existing units and hire in calibrated manner.

Every question, with its answer

  1. 1. Specialty ingredients & cost base

    Bansi Desai, J.P. Morgan

    Question. Specialty ingredients reported a decline this quarter — what's the reason and outlook for the year? Also on costs, employee and other expenses both declined YoY — is this a sustainable base?

    Answer, Ajay Bhardwaj, MD & CEO. Specialty ingredients capacity is fungible with CRDMO. CRDMO has been busy, so specialty inputs were diverted. Business is healthy and consistently trending upwards; expects it to hold up for rest of year. CFO Gawir Baig added that Unit-II expansion (~130 KL across CP 6 and CP 7) is now complete, giving adequate capacity for both. On employee cost, H1 FY25 included ~Rs 36 Cr ESOP charge (first-year allotment); FY26 ESOP is ~Rs 16 Cr (Rs 4 Cr per quarter). Net of ESOP, employee cost ~12.5% of sales in both halves. Other expenses broadly in line with H1 FY25.

    Follow-up. ESOP cost - is Rs 4 Cr per quarter likely to come down further next year?

    Answer. Yes. ~90% of the pool is on a sliding scale; Rs 36 Cr last year, Rs 16 Cr this year split Rs 4 Cr each, going forward it will come down further.

  2. 2. Capacity revenue potential

    Nikhil Mathur, HDFC Mutual Fund

    Question. With CP 6 and CP 7 commissioned, what's the revenue potential from these additions? Also, how is Unit-III (NeoAnthem) shaping up — suspecting it may not be fully utilized yet?

    Answer, Gawir Baig, Chief Financial Officer. CP 6 + CP 7 ~130 KL commissioned, ~Rs 182 Cr capex, completely unutilized currently. Based on 1.6-1.7x asset turnover, revenue potential ~Rs 300 Cr+. NeoAnthem gross block + CWIP Rs 350 Cr as of 30 Sept 2025; with additional fermentation blocks to be commissioned, gross block will reach ~Rs 450 Cr+. Long-term target 1.4-1.5x asset turnover on Rs 450 Cr base = ~Rs 650 Cr revenue. CEO Ajay added Unit-III has good WIP and many POs coming in; trending significantly upwards but not yet in profitable zone.

    Follow-up. Given ~Rs 450 Cr gross block to absorb over 2-3 years and industry talking about better RFP inflows to Indian CRDMOs, Anthem is not at a loss of capacity for new RFPs?

    Answer. Yes. 'Build it and they will come.' Anthem is ready with capacities to service new RFPs; has had surprisingly good new inquiries and is enthused by them.

  3. 3. Unit-IV timeline

    Nikhil Mathur, HDFC Mutual Fund

    Question. Longer-term on Unit-IV — the land parcel is in the books. How will it shape up, when do you pursue orders, and when do you expect first revenue?

    Answer, Ajay Bhardwaj, MD & CEO. Work has already started on Unit-IV; civil works in very good shape. Greenfield project, significant investment ~Rs 1,000 Cr. Positioning Anthem to become a leading/significantly important player. On track for commissioning within two years.

    Follow-up. Pre-Unit-IV, how many manufacturing/R&D employees do you need to add? Is current headcount adequate for envisaged next-2-year orders?

    Answer. Will need to add people as Unit-III expands and Unit-IV comes up. Mindful, careful hirers — transfer trained people from Unit-I/II to new units and train new people under them. Heavy investment in training. Will hire as needed.

  4. 4. Margin sustainability

    Nikhil Mathur, HDFC Mutual Fund

    Question. If employee additions are calibrated and revenue grows 2-3 years out, are current margins sustainable?

    Answer, Gawir Baig, Chief Financial Officer. Anthem among the lowest in industry on employee cost as % of sales. Base additions won't change ratio. Does not anticipate margin compression; will hold margins as in the past. CEO Ajay added EBITDA growth has been healthy and is expected to continue.

  5. 5. Pipeline & commercial molecules

    Saion Mukherjee, Nomura

    Question. Pipeline color on Phase 3 assets and how to think about commercial quantities. In existing commercial products, should we expect steady ~20% growth or any volatility?

    Answer, Ajay Bhardwaj, MD & CEO. At IPO in July, had 10 commercial molecules; Q1 went to 12 (2 added); last quarter 2 more — now 14 commercial molecules, 40% growth. Had 10 late-phase at listing; now 6 late-phase (4 moved to commercial). Funnel healthy with new customers moving from early to mid stage; some late-stage moving to Phase 3. Currently have good order book; customers doing well. Some molecules could be blockbusters but takes time. Confident of delivering earnings and revenue growth.

    Follow-up. Any visibility on when remaining 6 late-stage assets will go commercial?

    Answer. Not in Anthem's hands; entirely controlled by FDA and customers. Most are biotechs with cash burn keen to push approvals. No visibility on approval timing. Expect some good sales from second-source opportunities on existing customer molecules.

    Partly answered.

  6. 6. Margin guidance

    Saion Mukherjee, Nomura

    Question. On margins: 35-40% guidance, with new facilities coming and potential FX benefit, should we think about upper end? How to think about margins in coming quarters and next year?

    Answer, Gawir Baig, Chief Financial Officer. H1 EBITDA margin 41.4% includes ~2-3% from FX (forex net ~Rs 34 Cr). Underlying improvement from employee cost reduction, other expense reduction, product mix. Will be at upper end of 36-37% guided range for the full year. Various cost elements shouldn't increase significantly as % of sales.

  7. 7. Revenue mix disclosure

    Gourav Bhama, JM Financial

    Question. In the presentation, 56.4% commercial molecules contribution to revenue and 9.8% R&D services contribution — is this on a quarter basis or half-yearly basis?

    Answer, Gawir Baig, Chief Financial Officer. This is half year.

  8. 8. Biosimilars & GLP-1 opportunity

    Damayanti Kerai, HSBC

    Question. Update on biosimilars and generic GLP semaglutide opportunities — do they contribute meaningfully in near term?

    Answer, Ajay Bhardwaj, MD & CEO. Progressing steadily. Need to produce PV batches then get plant FDA-approved. Won't happen in next two quarters, but positive traction after that. Anthem fully backward integrated — develops the fermentation fragment itself (not relying on Chinese sourcing like most players), giving advantage on cost of goods. Most vertically integrated. Sampled many customers with ambitious plans; expects to supply GLP-1 to customers in India.

    Follow-up. When India innovator patents expire next year, could this be a meaningful revenue addition?

    Answer. Yes, absolutely. It will add to revenues. Everybody expects it to be a significant product.

  9. 9. Repurposed plant

    Damayanti Kerai, HSBC

    Question. Status of the unutilized plant you indicated would be repurposed — what's happening with it?

    Answer, Ajay Bhardwaj, MD & CEO. That plant is being repurposed for biosimilars. Completely retooled without significant investment to develop a biosimilar which is already a marketed biosimilar. Anthem will be the second source (and effectively first as the innovator shifts production out of the West).

    Follow-up. Beyond Rs 1,000 Cr Unit-IV capex over next 1-2 years, what other capex do you foresee?

    Answer. Largely Unit-IV. Unit-II is complete. Unit-III fermentation completes by year-end. Major capex is Rs 1,000 Cr Unit-IV Phase 1. Replacement capex not significant as a portion is expensed as repairs/maintenance.

  10. 10. Inventory decline

    Tushar, Motilal Oswal Financial Services

    Question. Inventory much lower vs March '25 — can you elaborate?

    Answer, Gawir Baig, Chief Financial Officer. A portion of a particular product was being sourced from an outsourced vendor (client-approved). Got approvals this year to manufacture the intermediate in-house, so the outsourced vendor inventory reduced and got replaced with raw materials as in-house mfg started. Additionally, customers asked to reduce inventory of certain products (filed commercial supplies) — inventory days brought down to ~105 days vs H1 FY25 and FY25.

    Follow-up. Does the inventory step-down imply temporary supply constraints on existing molecules — should base molecules take time to pick up again while new molecules ramp?

    Answer. Two-part answer: (1) Four new commercialized molecules will take time to deliver significant numbers — clients planning launches across markets. (2) Existing 10 molecules — products doing well with significant growth. Customer inventory normalization drove some reduction but overall supplies continue to grow; new products help further.

  11. 11. Unit-III regulatory scope

    Tushar, Motilal Oswal Financial Services

    Question. Unit-III — which geographies do products apply from a regulatory standpoint?

    Answer, Ajay Bhardwaj, MD & CEO. Unit-III will also focus on highly regulated markets. One system followed across units. While waiting for FDA inspection, supplying quantities for studies (as was done for Unit-II). Expects to file 1-2 projects soon for FDA inspection. Aim to supply regulated markets. GLP-1 and other products will also supply rest of world. Highest level of cGMP maintained.

    Follow-up. So meaningful revenue from Unit-III should be considered only after stability data and product qualification — FY28 timeline?

    Answer. Already ~Rs 55 Cr WIP in Unit-III, hopes to add a few tens more. Wants to push to Rs 100-150 Cr by then, after which files product and gets FDA inspection, then big revenue kick-up as commercial molecules come in. Building Unit-III sales today.

  12. 12. Unit-III business nature

    Tushar, Motilal Oswal Financial Services

    Question. This WIP is more lab business given products are under development?

    Answer, Ajay Bhardwaj, MD & CEO. No, it's pilot scale business. Quantities of 5, 10, 20, 30 kg used for day filings etc. Also supplies rest-of-world and uses Unit-III for specialty ingredients. Wants the asset to sweat quickly.

  13. 13. Geography mix & US biotech funding

    Srinath, Spark Asia Impact Managers Private Limited

    Question. How have sales been for European and North American markets QoQ and YoY? Any impact on R&D spending by US biotech companies due to funding environment?

    Answer, Gawir Baig, Chief Financial Officer. Europe sales highest, followed by US — but clients are global giants; supply based on their requirement across geographies, not regional customers. H1 Europe sales grew ~25% YoY vs H1 FY25; US sales also grew similarly. CEO Ajay added: mixed voices from clients. New funding available, 'winds changing.' Investors more selective now vs past when any project got funded. Steady flow of good new customers. Not unduly worried.

    Follow-up. Utilization levels for custom synthesis and fermentation for the quarter?

    Answer. Same as disclosed in prospectus — custom synthesis ~70% utilization on existing base (ex CP 6/7), fermentation ~55%. Expects new fermentation addition to allow customer orders to flow in next quarter or by year-end.

  14. 14. Unit-IV capacity translation

    Bansi Desai, J.P. Morgan

    Question. On Unit-IV Rs 1,000 Cr capex — what does this translate to in capacity?

    Answer, Gawir Baig, Chief Financial Officer. Custom synthesis ~400 KL give or take, fermentation ~100 KL give or take. Initial plan; mix could change as civil work progresses. CEO added: flexible and agile; builds shells that can be internally modified before equipment orders. Fermentation may go up to 100-200 KL depending on projects; custom synthesis 400 KL. Will roughly double capacities in Phase 1.

    Follow-up. All of this should get commissioned in next two years?

    Answer. Yes, absolutely. That's the goal.

  15. 15. Peptide capacity expansion

    Bansi Desai, J.P. Morgan

    Question. On peptides — 16 KL today plus NeoAnthem coming in. Plans to further scale up in Unit-IV, especially peptides/GLP-1?

    Answer, Ajay Bhardwaj, MD & CEO. In Unit-III itself peptides can be doubled — kept room. Builds shells, finishes civil work so fit-outs can come quickly. If needed, fit-outs in 6 months; 16 KL can become 32 or even 40 KL. Unit-IV adds more fermentation, sum can go into fermentation part of GLP/peptides. Plans capacity that can quadruple or at least triple current capacity.

    Follow-up. On large customers — you mentioned relationships with 3 of top 5. Added any more, maybe in early stage?

    Answer. Yes, absolutely. Without naming them, has major engagement going on with two major global pharma companies (really major) which will show dividends not immediately but in near term.

    Partly answered.

  16. 16. Peptide program mix

    Sanjay Kumar, Ithought PMS

    Question. On peptides — you have 10 peptide programs. Breakup of GLP-1s vs other therapies (peptide drug conjugates, etc.)?

    Answer, Gawir Baig, Chief Financial Officer. 10 peptide programs are all non-GLP novel peptides for CDMO customers, early stage. The commercial facility was built to service them as they move from early to late to commercial. GLP opportunity taken up as a separate program due to fermentation capability and backward integration. CEO Ajay added: peptides a big runway beyond GLP-1 — oncology, metabolism, heart, obesity. Innovators confident future is peptides. Time frames 2-5 years.

    Follow-up. Generic GLP-1s — done process validation for semaglutide? Going to file DMF? Any signed deals for generic sema?

    Answer. Doing PV. No deals signed at moment. Working with companies (including very big players) to be in supply chain — will happen for sure.

  17. 17. Peptide technical capability

    Sanjay Kumar, Ithought PMS

    Question. On peptide capabilities — what peptide length can you synthesize? Continuous/hybrid synthesis? Backward integrated means in-house amino acid production?

    Answer, Ajay Bhardwaj, MD & CEO. Not making amino acids — different business. Many peptides are biosynthetic — fermentation bit followed by synthesis bit. Anthem develops the fermentation bit. Example: semaglutide P29 fragment is fermentation — 29 amino acids constructed by fermentation. Most peptide players don't have this; need large-scale fermentation. Anthem's strategy: makes P29 plus assembly — fully integrated. Will not make amino acids.

  18. 18. Forward growth sustainability

    Ankush Mahajan, Unknown

    Question. H1 saw 26% revenue growth, 4 new commercial molecules, CP 6+CP 7 130 KL already installed, plus Unit-III Rs 350 Cr + Rs 100 Cr capex. Can we see similar revenue growth for next 6 months and FY27?

    Answer, Ajay Bhardwaj, MD & CEO. 4 new commercial molecules just recently approved — supplied quantities, depends on customers. Some in pre-launch, working out strategies. Biotech cos often get acquired after approval — beyond Anthem's control. History: ~20% CAGR over last 10-15 years; hopes to maintain. Quarters can be lumpy — some quarters exceptional (customer bunches orders), some down. Asks investors to bear QoQ variations in mind over next 5-10 years; Anthem has always trended upwards and will continue this year.

What was said

Topic by topic, in the order it was spoken

H1 FY26 Financial Highlights · Ajay Bhardwaj (MD & CEO)

  • Consolidated H1 FY26 revenue Rs 1,090 Cr — CRDMO Rs 926 Cr, specialty ingredients Rs 163 Cr
  • EBITDA Rs 480 Cr at 41.4% margin; PAT Rs 309 Cr at 26.6% PAT margin
  • Other income Rs 71 Cr; net cash position Rs 993 Cr as on 30 Sept 2025
  • Management expressed confidence in delivering further growth for the rest of FY26

Q&A Session (combined) · Ajay Bhardwaj and Gawir Baig

  • Capacity build (CP6/CP7, Unit-III NeoAnthem, Unit-IV greenfield) dominated discussion
  • Pipeline evolution — 14 commercial molecules, 6 late-phase; Phase 3 visibility limited
  • Peptide/GLP-1 and biosimilar strategy with full backward integration via fermentation
  • Margin guidance reaffirmed at upper end of 36-37% band; H1 ~38-39% underlying excluding FX

In their words

In our business we have to build it and then they will come. We are ready with capacities to service new RFPs. You're right, we have had surprisingly some good new inquiries, which we are very enthused by.
Ajay Bhardwaj (MD & CEO, Anthem Biosciences)
Our CAGR is 20% odd there for the last 10-15 years. We hope to be able to maintain that and that is what we are focused on. At the end of the year, in our business, quarters can be lumpy. Some quarters can be exceptional because customers say, I want all this in this quarter. But, in other quarters, it can be a little down.
Ajay Bhardwaj (MD & CEO, Anthem Biosciences)
Anthem will arguably have one of the strongest positions in this space, because we are fully integrated all the way backward... we will be most vertically integrated among these players.
Ajay Bhardwaj (MD & CEO, Anthem Biosciences)

To check next time

What management committed to on this call, or the dates they gave.

  • Q3 FY26 specialty ingredients recovery as CP 6/CP 7 capacity is now available for both segments.
  • Unit-III fermentation block completion by end of calendar 2025; revenue trajectory toward Rs 100-150 cr target.
  • EBITDA margin trend - whether 36-37% normalized margin holds as FX benefit (~Rs 34 cr) may not repeat.
  • Movement of remaining 6 late phase molecules to commercial; capacity to absorb new RFPs.
  • ESOP charge trajectory - expected to come down further from Rs 4 cr per quarter as options vest.
  • Unit-IV civil works progress; order pipeline for the new Rs 1,000 cr capacity.

Transcript

We have not transcribed this call's recording. Read the company's transcript (PDF).

The stock after the call

After the callCloseStockNifty 50
Next session Mon 10 Nov 2025₹704.95+1.21%+0.32%
5 sessions Fri 14 Nov 2025₹678.90−2.53%+1.64%
20 sessions Fri 5 Dec 2025₹654.45−6.04%+2.72%

From the close of Fri 7 Nov 2025, ₹696.55: the close before the call day (the call's time is not on file). Adjusted daily closes; the move includes everything else that happened in those sessions.

Anthem Biosciences's other calls